| Catalog No. | HY286676 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FCM, Functional assay, Research in vivo |
|---|
| Host species | Human |
|---|
| Clonality | Monoclonal |
|---|
| Isotype | IgG |
|---|
| Clone ID | H2Mab-139 |
|---|
| Biological activity |
H 2 Mab-139 (10 ug/mL; 30 min at 4°C) specifically binds to HER2 on LN229/HER2 glioblastoma cells and the colorectal cancer cell lines Caco-2, HCT-116, HCT-15, HT-29, LS 174T, COLO 201, COLO 205, HCT-8, SW1116, and DLD-1 in flow cytometry assays [1]. H2Mab-139 (10 ug/mL) specifically detects HER2 protein with a molecular weight of approximately 200 kDa in LN229/HER2 glioblastoma cell lysates via Western blotting [1]. H2Mab-139 (10 ug/mL; 1 h at room temperature) specifically stains the cell membrane of HER2-positive human colon cancer tissue sections in immunohistochemical assays [1]. H2Mab-19 (6 ng/mL to 100 ug/mL) maintains high binding affinity for HER2 in HER2-expressing BT-474, HSC-2, and SAS cell lines, with K d values of 2.3 × 10 -8 M, 9.5 × 10 -9 M, and 5.5 × 10 -9 M, respectively [2]. H2Mab-19 (5 h at 37°C) exhibits high CDC activity against BT-474, HSC-2 and SAS cell lines, with cytotoxicity rates of 46%, 51% and 53%, respectively [2]. H2Mab-19 (100 ug per dose; i.p.; on days 1, 7, and 14 after cell implantation) significantly reduces tumor development and tumor weight in BT-474 breast cancer xenografts [2]. H2Mab-19 (100 ug per dose; i.p.; on days 1, 6, and 14 after cell implantation) significantly reduces tumor development and tumor weight in HSC-2 oral cancer xenografts [2]. |
| Target |
CD340, EC:2.7.10.1, ERBB2, HER2, MLN 19, MLN19, Metastatic lymph node gene 19 protein, NEU, NGL, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Receptor tyrosine-protein kinase erbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2 |
| Endotoxin level |
< 10 EU/mg |
| Purity |
>95% as determined by SDS-PAGE. |
| Purification |
Protein A/G purified from cell culture supernatant. |
| Accession |
P04626 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternate Names | H2Mab-139, H2Mab139, H2Mab139 |
|---|
| Background | Receptor tyrosine-protein kinase erbB-2 (CD340/ERBB2) is a ~137 kDa protein. Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. CD340 is the therapeutic target of trastuzumab (Herceptin) and trastuzumab deruxtecan (Enhertu). |
|---|
| References |
1. Kaneko MK, et al. Development of an Anti-HER2 Monoclonal Antibody H2Mab-139 Against Colon Cancer. Monoclon Antib Immunodiagn Immunother. 2018;37(1):59-62. [HY286676]
2. Takei J, et al. H 2 Mab-19, an anti-human epidermal growth factor receptor 2 monoclonal antibody exerts antitumor activity in mouse oral cancer xenografts. Exp Ther Med. 2020;20(2):846-853. [HY286676] |
| Note |
For research use only. Not suitable for clinical or therapeutic use. |
中文
English
한국어
日本語
Español
Français
Русский
